Datopotamab Deruxtecan Jointly Developed By Daiichi Sankyo And Astrazeneca Met Dual Primary Endpoint Of Progression-Free Survival In Patients With Advanced Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
Portfolio Pulse from Benzinga Newsdesk
Datopotamab Deruxtecan, a drug jointly developed by Daiichi Sankyo and AstraZeneca, has met its dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in the TROPION-Lung01 Phase 3 trial.
July 03, 2023 | 6:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's jointly developed drug, Datopotamab Deruxtecan, has shown positive results in Phase 3 trial for advanced non-small cell lung cancer.
The positive results from the Phase 3 trial of Datopotamab Deruxtecan, a drug jointly developed by AstraZeneca, could potentially boost the company's stock as it indicates a successful development and potential future sales.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Daiichi Sankyo's jointly developed drug, Datopotamab Deruxtecan, has shown positive results in Phase 3 trial for advanced non-small cell lung cancer.
The positive results from the Phase 3 trial of Datopotamab Deruxtecan, a drug jointly developed by Daiichi Sankyo, could potentially boost the company's stock as it indicates a successful development and potential future sales.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50